Trial · NCT02258542
Results by group402
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 402
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | -0.005 | Standard Deviation 0.0223 | 10^9 cells/L | |
| Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | -0.005 | Standard Deviation 0.0239 | 10^9 cells/L | |
| Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients | ZONDA - Benralizumab 30 mg q.4 Weeks | -0.007 | Standard Deviation 0.0283 | 10^9 cells/L | |
| Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients | ZONDA - Benralizumab 30 mg q.8 Weeks | -0.005 | Standard Deviation 0.0244 | 10^9 cells/L | |
| Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | -0.006 | Standard Deviation 0.0145 | 10^9 cells/L | |
| Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 0.001 | Standard Deviation 0.0208 | 10^9 cells/L | |
| Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | -0.344 | Standard Deviation 2.0412 | 10^9 cells/L | |
| Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | -0.128 | Standard Deviation 1.8614 | 10^9 cells/L | |
| Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients | ZONDA - Benralizumab 30 mg q.4 Weeks | -0.808 | Standard Deviation 1.8177 | 10^9 cells/L | |
| Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients | ZONDA - Benralizumab 30 mg q.8 Weeks | -0.507 | Standard Deviation 3.3612 | 10^9 cells/L | |
| Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | -0.487 | Standard Deviation 1.7289 | 10^9 cells/L | |
| Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | -0.079 | Standard Deviation 1.8432 | 10^9 cells/L | |
| Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | -0.032 | Standard Deviation 0.6242 | 10^9 cells/L | |
| Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 0.003 | Standard Deviation 0.5402 | 10^9 cells/L | |
| Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients | ZONDA - Benralizumab 30 mg q.4 Weeks | -0.093 | Standard Deviation 0.6403 | 10^9 cells/L | |
| Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients | ZONDA - Benralizumab 30 mg q.8 Weeks | 0.007 | Standard Deviation 0.6864 | 10^9 cells/L | |
| Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | -0.180 | Standard Deviation 0.6946 | 10^9 cells/L | |
| Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | -0.070 | Standard Deviation 0.6671 | 10^9 cells/L | |
| Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks | -0.171 | Standard Deviation 1.8746 | 10^9 cells/L | |
| Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients | SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks | 0.013 | Standard Deviation 1.7024 | 10^9 cells/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02258542/results